Enanta Pharmaceuticals is using its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are focused on the following disease targets: respiratory syncytial virus (RSV)hepatitis B virus (HBV),  SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie, as part of its leading treatment for chronic HCV infection under the trade names MAVYRET® (U.S) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir).

View our pipeline.

Enanta is headquartered in Watertown, Massachusetts.